IRulya Therapeutics, Inc. (IRLA)
32.95
+1.33
(+4.21%)
USD |
NASDAQ |
Oct 30, 16:00
33.50
+0.55
(+1.67%)
After-Hours: 20:00
IRulya Therapeutics Shareholders Equity (Quarterly) : 108.49M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 108.49M |
| March 31, 2026 | 15.67M |
| December 31, 2025 | -35.71M |
| September 30, 2025 | 1.059M |
| June 30, 2025 | 11.74M |
| March 31, 2025 | 18.58M |
| December 31, 2024 | 30.15M |
| September 30, 2024 | 44.93M |
| June 30, 2024 | 46.97M |
| March 31, 2024 | 74.18M |
| December 31, 2023 | 85.08M |
| September 30, 2023 | 83.13M |
| June 30, 2023 | 86.88M |
| March 31, 2023 | 90.20M |
| December 31, 2022 | 100.59M |
| Date | Value |
|---|---|
| September 30, 2022 | 104.53M |
| June 30, 2022 | 111.53M |
| March 31, 2022 | 106.38M |
| December 31, 2021 | 118.59M |
| September 30, 2021 | 132.65M |
| June 30, 2021 | 142.08M |
| March 31, 2021 | 156.48M |
| December 31, 2020 | 172.26M |
| September 30, 2020 | 188.01M |
| June 30, 2020 | 205.47M |
| March 31, 2020 | 218.04M |
| December 31, 2019 | 115.48M |
| September 30, 2019 | 127.29M |
| June 30, 2019 | 136.22M |
| March 31, 2019 | 66.11M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Korsana Biosciences, Inc. | 5.087M |
| PepGen Inc. | 119.53M |
| Q32 Bio, Inc. | 105.90M |
| Bridgebio Oncology Therapeutics, Inc. | 323.11M |
| Arrowhead Pharmaceuticals, Inc. | 465.53M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 124.00M |
| Total Liabilities (Quarterly) | 15.51M |
| Current Ratio | 14.52 |
| Net Debt Paydown Yield | 17.03% |